Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Otjacques, Eléonore ^a   Binsfeld, Marilène ^a   Rocks, Natacha ^a   Blacher, Silvia ^a   Vanderkerken, Karin ^b   Noel, Agnès ^a   Beguin, Yves ^a   Cataldo, Didier ^a   Caers, Jo ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MITHRAMYCIN; MYC PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; RAT; UPREGULATION; VASCULAR RING;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; BONE MARROW CELLS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; HUMANS; MICE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PHYSIOLOGIC; PLICAMYCIN; RATS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877107354     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062818     Document Type: Article

References (47)

1. Caers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, et al. (2008) Multiple myeloma-an update on diagnosis and treatment. Eur J Haematol 81: 329-343.
2. Chesi M, Bergsagel PL, (2011) Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program 2011: 344-353.
3. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, et al. (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106: 296-303.
4. Anderson KC, Carrasco RD, (2011) Pathogenesis of myeloma. Annu Rev Pathol 6: 249-274.
5. Otjacques E, Binsfeld M, Noel A, Beguin Y, Cataldo D, et al. (2011) Biological aspects of angiogenesis in multiple myeloma. Int J Hematol 94: 505-518.
6. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, et al. (1994) Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87: 503-508.
7. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, et al. (2002) Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8: 2210-2216.
8. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, et al. (2009) Induction of angiogenesis by normal and malignant plasma cells. Blood 114: 128-143.
9. Lombo F, Menendez N, Salas JA, Mendez C, (2006) The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives. Appl Microbiol Biotechnol 73: 1-14.
10. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, et al. (1991) Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 88: 1613-1621.
11. Snyder RC, Ray R, Blume S, Miller DM, (1991) Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters. Biochemistry 30: 4290-4297.
12. Yuan P, Wang L, Wei D, Zhang J, Jia Z, et al. (2007) Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 110: 2682-2690.
13. Gao Y, Jia Z, Kong X, Li Q, Chang DZ, et al. (2011) Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res 71: 5182-5193.
14. Malek A, Nunez LE, Magistri M, Brambilla L, Jovic S, et al. (2012) Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS One 7: e35130.
15. Previdi S, Malek A, Albertini V, Riva C, Capella C, et al. (2010) Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol 118: 182-188.
16. Garrett IR, Dallas S, Radl J, Mundy GR, (1997) A murine model of human myeloma bone disease. Bone 20: 515-520.
17. Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM, (1988) Animal model of human disease. Multiple myeloma. Am J Pathol 132: 593-597.
18. Radl J, De Glopper ED, Schuit HR, Zurcher C, (1979) Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 122: 609-613.
19. Oyajobi BO, Munoz S, Kakonen R, Williams PJ, Gupta A, et al. (2007) Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 6: 1701-1708.
20. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, et al. (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. 2000/09/09: 2240-2245.
21. Rocks N, Paulissen G, Quesada-Calvo F, Munaut C, Gonzalez M-LA, et al. (2008) ADAMTS-1 Metalloproteinase Promotes Tumor Development through the Induction of a Stromal Reaction In vivo. Cancer Research 68: 9541-9550.
22. Masson VV, Devy L, Grignet-Debrus C, Bernt S, Bajou K, et al. (2002) Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biol Proced Online 4: 24-31.
23. Blacher S, Devy L, Burbridge MF, Roland G, Tucker G, et al. (2001) Improved quantification of angiogenesis in the rat aortic ring assay. Angiogenesis 4: 133-142.
24. Detry B, Erpicum C, Paupert J, Blacher S, Maillard C, et al. (2012) Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood 119: 5048-5056.
25. Van Valckenborgh E, De Raeve H, Devy L, Blacher S, Munaut C, et al. (2002) Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer 86: 796-802.
26. Farnebo M, Bykov VJ, Wiman KG, (2010) The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 396: 85-89.
27. Deshpande A, Sicinski P, Hinds PW, (2005) Cyclins and cdks in development and cancer: a perspective. Oncogene 24: 2909-2915.
28. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, et al. (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182: 155-162.
29. Gerlo S, Haegeman G, Vanden Berghe W, (2008) Transcriptional regulation of autocrine IL-6 expression in multiple myeloma cells. Cell Signal 20: 1489-1496.
30. Fulciniti M, Amin S, Nanjappa P, Rodig S, Prabhala R, et al. (2011) Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res 17: 6500-6509.
31. Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, et al. (2005) Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 65: 11345-11353.
32. Safe S, Abdelrahim M, (2005) Sp transcription factor family and its role in cancer. Eur J Cancer 41: 2438-2448.
33. Koutsodontis G, Kardassis D, (2004) Inhibition of p53-mediated transcriptional responses by mithramycin A. Oncogene. 23: 9190-9200.
34. Ohgami T, Kato K, Kobayashi H, Sonoda K, Inoue T, et al. (2010) Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers. Cancer Sci 101: 1387-1395.
35. Jia Z, Zhang J, Wei D, Wang L, Yuan P, et al. (2007) Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res. 67: 4878-4885.
36. Wang L, Guan X, Zhang J, Jia Z, Wei D, et al. (2008) Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int J Oncol 33: 161-167.
37. Ping D, Boekhoudt G, Zhang F, Morris A, Philipsen S, et al. (2000) Sp1 binding is critical for promoter assembly and activation of the MCP-1 gene by tumor necrosis factor. J Biol Chem 275: 1708-1714.
38. Spurrell JC, Wiehler S, Zaheer RS, Sanders SP, Proud D, (2005) Human airway epithelial cells produce IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection. Am J Physiol Lung Cell Mol Physiol 289: L85-95.
39. Ahn SY, Cho CH, Park KG, Lee HJ, Lee S, et al. (2004) Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression. Am J Pathol 164: 1663-1672.
40. Presta M, Belleri M, Vacca A, Ribatti D, (2002) Anti-angiogenic activity of the purine analog 6-thioguanine. Leukemia 16: 1490-1499.
41. Patten SG, Adamcic U, Lacombe K, Minhas K, Skowronski K, et al. (2010) VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. BMC Cancer 10 683: 10.1186/1471-2407-1110-1683.
42. Caers J, Menu E, De Raeve H, Lepage D, Van Valckenborgh E, et al. (2008) Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. Br J Cancer 98: 1966-1974.
43. Coluccia AML, Cirulli T, Neri P, Mangieri D, Colanardi MC, et al. (2008) Validation of PDGFRβ and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 112: 1346-1356.
44. Green L, Donehower RC, (1984) Hepatic toxicity of low doses of mithramycin in hypercalcemia. Cancer Treat Rep 68: 1379-1381.
45. Anthony ET, Kantaria S, Moir GC, Chopra S, (2009) The penetrative abilities of liposomal mithramycin in explanted keloids. Clin Exp Dermatol 34: 408-409.
46. Remsing LL, Gonzalez AM, Nur-e-Alam M, Fernandez-Lozano MJ, Brana AF, et al. (2003) Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis. J Am Chem Soc 125: 5745-5753.
47. Barcelo F, Ortiz-Lombardia M, Martorell M, Oliver M, Mendez C, et al. (2010) DNA binding characteristics of mithramycin and chromomycin analogues obtained by combinatorial biosynthesis. Biochemistry 49: 10543-10552.